Drugs / HLX87
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07294508 | Feb 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07294534 | Jan 2026 → Sep 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX87 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07294534 ↗ |
| Modality | Other / unclassified | “HLX87 is a novel HER2-targeted ADC” NCT07294534 ↗ |